The Polo-like kinases (Plks) are a conserved family of kinases that contribute to cell cycle regulation, particularly in G2 and mitosis. In mammals, there are at least three members of the Plk family. Here we show that Plk3 is a stress response protein that becomes phosphorylated following DNA damage or mitotic spindle disruption. Phosphorylation enhances its kinase activity and is dependent upon ataxia telangiectasiamutated (ATM) in the former case but not the latter. Plk3 associates with complexes of multiple sizes ranging from 150 to greater then 600 kDa. In its unphosphorylated form it elutes from a sizing column at about 400 kDa whereas it associates with complexes of 150 and 600 kDa when phosphorylated. Among the proteins with which it physically associates and utilizes, as substrates are Chk2 and P53. It phosphorylates Chk2 on a residue different from threonine 68 (Thr68), the principal target for ATM. While ATM is necessary for phosphorylation and activation of Chk2 in vivo, Plk3 seems to contribute to its full activation. In its phosphorylated form it also coelutes and forms a complex with unpolymerized tubulin. In aggregate, the data argue that Plk3 is a multifunctional protein that associates with multiple complexes and that contributes to response to stress incurred by DNA damage and mitotic spindle disruption, albeit via different pathways.
Introduction
The polo-like kinases are a family of serine/threonine kinases that are emerging as important regulators of cellular function. The founding member of this family is the product of the polo gene from Drosophila melanogaster (Sunkel and Glover, 1988) , which, when mutant, results in defects in spindle formation and chromosome segregation (Sunkel and Glover, 1988; Llamazares et al., 1991) as well as in cytokinesis (Carmena et al., 1998) . The polo kinases have in common a conserved 28-amino acid sequence, located at the carboxy end of the protein, that plays a role in its intracellular localization (Song and Lee, 2001 ). The protein kinase encoded by polo has homologs in a wide spectrum of eukaryotes ranging from Drosophilia to yeast to humans (for review : Nigg, 1998; Bahassi and Hennigan, 2001 ). These polo-like kinases (Plks) participate in a diverse range of mitotic functions, including entry into and exit from mitosis (Sunkel and Glover, 1988; Golsteyn et al., 1996) .
In S. cerevisiae there exists only a single Plk (Cdc 5) and the same presumably is true for S. pombe (Plo). In mammals there are at least three Plks (Plk1-3), formerly designated Plk, Snk and Fnk/Prk, respectively, of which Plk1 has been the most thoroughly investigated. Both Plk1 and Plk3 can complement an S. cerevisiae Cdc 5 temperature sensitive mutant (Ouyang et al., 1997) , suggestive of some commonality in function. However, overexpression of these proteins following transfection of their cDNAs into cells has diametrically opposite phenotypic effects, indicative of divergent cellular activities. Transfection of NIH3T3 cells with a Plk1 cDNA results in their transformation and acquisition of the ability to form tumors in nude mice (Smith et al., 1997) . In contrast, transfection of mammalian cells with Plk3 cDNA results in cell death (Conn et al., 2000) .
Recently, the polo kinases have been implicated in cellular responses to DNA damage. In budding yeast, Cdc 5 undergoes post-translational modification in a Rad 53-dependent manner when grown under conditions that induce DNA damage (Cheng et al., 1998) , and independent evidence suggests that Rad 53-mediated checkpoint control operates through regulation of Cdc 5 (Sanchez et al., 1999) . In mammalian cells, Plk1 activity, which appears at the G2/M transition (Golsteyn et al., 1995) , is inhibited by DNA damage (Smits et al., 2000) , and this inhibition is dependent upon functional ATM (Smits, et al., 2000) . Considerably less information is available for Plk3. The levels of mouse Plk3 (Fnk) protein have been reported to progressively increase as cells proceed from G1 through S phase and G2, and the protein has been reported to become phosphorylated as cells enter mitosis (Chase et al., 1998) . Plk3 also appears to be activated when cells are exposed to H 2 O 2 , a reagent that produces reactive oxygen (Xie et al., 2001a) . In this study we show that Plk3 protein levels remain constant throughout the cell cycle in Hela cells, but that the protein becomes phosphorylated and activated following DNA damage and as a consequence of mitotic spindle disruption by Nocodazole. Response to DNA damage by ionizing radiation is mediated by ATM whereas the response to Nocodazole is not. To begin to place Plk3 within a signaling pathway following DNA damage, we have shown that Plk3 interacts with and phosphorylates both tumor suppressor proteins Chk2 and P53. Although Plk3 may have regulatory roles during the normal cell cycle, our data suggest that it is a protein that responds to stress and that has multiple downstream targets that can participate in cell cycle arrest.
Results

Plk3 is not detectably phosphorylated during cell cycle progression
Hela cells were synchronized at the G1/S boundary with a double thymidine block to assess whether or not Plk3 becomes phosphorylated during the cell cycle in the absence of any perturbation other than the synchronization protocol. Following release from the block, protein levels and phosphorylation status of Plk3 were determined at 2-h intervals. At each time interval, the cells were monitored by flow cytometry to verify their position in the cell cycle. Based on the flow cytometry and the appearance and rapid disappearance of cyclin B1 (Figure 1 ), tight cell synchrony persisted through G2 and mitosis. The expression level of Plk3 remained constant during the cell cycle and there were no slowly migrating bands as evidence of phosphorylation (Figure 1 ). The same experiment was performed with HT1080 cell and NIH3T3 cells with similar results. For comparison, the same analysis was carried out on Plk1 which, as previously described (Golsteyn et al., 1995) , fluctuated as a function of cell cycle.
Plk3 is phosphorylated in response to DNA damage in an ATM-dependent manner When cells are exposed to agents that damage DNA, such as ionizing radiation or methylmethane sulfonate (MMS), Plk3 is rapidly phosphorylated. Phosphorylation of Plk3 manifests as a more slowly migrating electrophoretic band that is lost or diminished after treatment with calf intestine phosphatase (Figure 2a) . When ATM proficient lymphoblastoid cells, heterozygous at ATM, were exposed to MMS, Plk3 became phosphorylated, whereas the ATM deficient counterpart, GM3189C, derived from a sibling, did not support Plk3 phosphorylation. The absence of Plk3 phosphorylation in an ATM deficient background suggests that ATM itself, or an effector downstream of ATM, is responsible for Plk3 phosphorylation after DNA damage (Figure 2b ). Consistent with this finding is the observation that irradiation in the presence of caffeine (10 mM), which inhibits ATM activity (Blasina et al., 1999b) , also prevents phosphorylation of Plk3 (Figure 2c ). Further analysis showed that Plk3 is not directly phosphorylated by ATM in vitro. Biochemically purified ATM failed to phosphorylate GST-Plk3 kinase dead (KD), yet it was able to phosphorylate both RepA and Chk2 (1-90), two known substrates for ATM in vivo (Figure 2d ). To assess the kinetics of Plk3 phosphorylation, Hela cells were subjected to Xirradiation for increasing times under conditions where time of exposure and total exposure are linearly related. A phosphorylated band was visible by 2 min (5 Gy). By 8 min (20 Gy) almost half of the Plk3 was in its phosphorylated form (Figure 2c ).
Phosphorylation of Plk3 in response to Nocodazolemediated spindle disruption is independent of ATM activity Our data showing an absence of detectable Plk3 phosphorylation during normal cell cycle progression differed from a previous report suggesting that phosphorylation occurs at the G2/M transition (Chase et al., 1998) . The experimental design between the two approaches differed in that the earlier report had used serum release from G 0 as well as Nocodazole for cell synchronization. Their observation led us to consider that Plk3 may be a stress responsive protein that responds not only to DNA damage but also to mitotic spindle disruption. Concomitantly, we wished to ask whether Plk3 was associated with intracellular protein complexes and whether or not such associations varied according to its phosphorylation status. Hela cells in exponential growth, or synchronized in prometaphase by exposure to Nocodazole, were lysed, and lysates were fractionated by FPLC and Superdex 200 column chromatography, which separates proteins and complexes between 5 and 680 kDa. Various lysate fractions were then subjected to Western blot analysis. Lysates from exponentially growing cells produced only a hypophosphorylated form of Plk3 that eluted with a molecular weight between 140 and 220 kDa ( Figure 3a ). Phosphatase treatment of this Plk3 caused no shift in mobility, consistent with minimal or absent phosphorylation (data not shown). When cells were treated with Nocodazole, the Plk3 protein eluted at three different molecular weight ranges (Figure 3a ). Plk3 eluted primarily in its phosphorylated form in the range of 140 to 200 kDa, suggestive of a dimeric or trimeric complex. A phosphorylated form also eluted in fractions containing high molecular weight complexes (fractions 7 and 8) of 600 kDa and greater. The unphosphorylated form of Plk3 elutes in fractions 10 and 11 at molecular weights between about 400 and 500 kDa, suggestive of an association with yet a different sub-cellular complex ( Figure 3a) . CIP treatment of the phosphorylated form of Plk3 led to the appearance of a band that has the same size as the unphosphorylated form of Plk3 (Figure 3b ). Consistent with a role in the Nocodazole-mediated arrest, the phosphorylated Plk3 co-immunopreciptated with unpo- Figure 2 Plk3 is phosphorylated in response to DNA damage in an ATM dependent manner. Cells were exposed to ionizing radiation (20 Gy) or methylmethane sulfonate (50 mg/ml) and cell lysates monitored by Western blot with anti-Plk3 antibody. Phosphorylation of Plk3 in response to DNA damage is dependent upon ATM. To determine whether phosphorylation in response to mitotic spindle disruption was also ATM dependent or whether this phosphorylation is mediated by another pathway, the ATM deficient lymphoblastoid cell line, GM3189C and its heterozygous counterpart, GM3323C, were treated with Nocozadole for 8 h and Plk3 was assayed for its phosphorylation status. Unlike results following ionizing radiation, Plk3 became equally phosphorylated in both the ATM-deficient and ATM-proficient cell lines (Figure 3d ) indicating that Plk3 phosphorylation in response to DNA damage and to spindle disruption occurs by different signaling pathways.
Plk3 phosphorylates Chk2 in vitro
The Chk2 tumor suppressor has been implicated in checkpoint responses in mammalian cells (Matsuoka et al., 1998; Blasina et al., 1999a) . Phosphorylation of Cdc25c by either Chk2 or Chk1 inactivates its phosphatase activity and requires the upstream participation of ATM. (Matsuoka et al., 1998; Blasina et al., 1999a; Sanchez et al., 1997) . Although phosphorylation of Chk2 at Threonine 68 is mediated by ATM (Melchionna et al., 2000) , involvement of other kinases in its activation has not been ruled out. Because of its rapid activation by ionizing radiation, Plk3 is a prospective candidate for such a kinase. With this in mind, Chk2 was tested as a substrate for Plk3 kinase activity in vitro. As seen in Figure 4a , Plk3 was able to phosphorylate in vitro a kinase dead mutant GST-Chk2KD fusion protein. The preferred site of Chk2 phosphorylation by ATM is threonine 68 (Melchionna et al., 2000) . To establish whether or not the same is true for phosphorylation by Plk3 in vitro, several GST-Chk2 truncations were tested for their capacity to be phosphorylated by Plk3 ( Figure  4b ). The Chk2 fragment containing residues 1 through 90 was the most robustly phosphorylated followed by the fragment extending from 1 through 190. The reduced phosphorylation of the longer fragment may result from a conformational change that impedes its phosphorylation. A 330-residue carboxy terminal fragment, extending from 190 to the terminus was not visibly phosphorylated. The amino terminal region of Chk2 contains a cluster of SQ/TQ motifs, especially Thr68 residue required for its phosphorylation and activation after ionizing radiation. Using mutants of the 1 -90aa Chk2 fragment with ATM/ATR preferred phosphorylation sites altered (T68A, S51A, and S23,28A), there was no significant diminution of in vitro phosphorylation by Plk3 compared with the wild type fragment (Figure 4c ). This result persisted even when substrate concentrations were reduced to one tenth that of the Plk3 kinase (Figure 4d) . Thus, if Chk2 T68 is a substrate site for Plk3 in vitro, it cannot be the only residue that is phosphorylated.
Plk3 interacts with Chk2 and participates in its full activation in vivo
That Plk3 phosphorylates Chk2 in vitro suggests that the two proteins physically interact in vivo. Coimmunoprecipitation with polyclonal Chk2 antibody, but not with IgG control antibody, precipitated Plk3 from lysates of T47D cells (Figure 5a ). To examine whether Plk3 directly targets Chk2 in vivo or acts upstream of Chk2 during the response to DNA damage, we used Daudi cells, a lymphoblastic leukemic cell line previously reported to express no detectable levels of Plk3 (Xie et al., 2001a) and T47D cells a breast cancer cell line that shows a robust expression of Plk3 (Figure 5b ) as well as the ATM deficient lymphoblastoid cell line, GM 3189C, and its heterozygous counterpart, 3323C. In addition, the DNA-PK deficient and heterozygous cell lines were used. All cell lines were exposed to 20 Gy of ionizing radiation, and following 1-h recovery, were lysed and subjected to immunoprecipitation with a Chk2 polyclonal antibody. In vitro kinase assay using point mutations of the GST-Chk2 fragment containing amino acids 1 through 90. The first three lanes use a kinase dead version of Plk3; the second three lanes use wild type GSTPlk3. The last two lanes show in vitro kinase activity in the non-mutant Chk2 1-90 fragment using kinase dead and wild type Plk3, respectively. There was no significant diminution of in vitro phosphorylation of Chk2 mutants by Plk3 even when substrate concentrations were reduced to one tenth that of the Plk3 kinase (d)
The catalytic activity of immunoprecipitated Chk2 from each cell lysate was examined in vitro using the Cdc25c peptide including residues 200 through 256 (Figure 5b ). The Chk2 kinase activity in the ATM deficient cell line was very low, consistent with ATM kinase being the primary in vivo activator of Chk2. The Plk3 deficient cell line showed reduced Chk2 activation compared with T47D, consistent with a role for Plk3 in Chk2 activation. The DNA-PK deficient cell line also showed a reduction in the Chk2 kinase activity compared with its wild type counterpart, consistent with in vitro data showing that Chk2 is phosphorylated on Thr68 by DNA-PK (Melchionna et al., 2000) . The levels of ATM and Plk3 were determined by Westernblot to ensure that the amount of these proteins in each cell line was as predicted (Figure 5b ).
Plk3 phosphorylates and interacts with P53
In an earlier report, we had noted that P53 could serve as a substrate for Plk3 kinase activity (Conn et al., 2000) prompting us to evaluate a possible role for Plk3 in P53 phosphorylation and activation. Phosphorylation of P53 by Plk3 was confirmed in an in vitro kinase assay using GFP-Plk3 and a kinase dead (KD) GFPPlk3 mutant. The wild type GFP-Plk3 showed a high kinase activity toward P53 whereas the kinase dead counterpart had no such activity (Figure 6b ). Two approaches were used to establish in vivo association between the two proteins. In the first instance cell lysates from X-irradiated cells and from exponentially growing cells were fractionated on a sizing column (Superdex 200) and fractions probed for Plk3 and P53 (Figure 6a) . The hyperphosphorylated form of P53 following ionizing radiation co-fractionated with Plk3 at a molecular weight of roughly 150 kDa, a size consistent with a heterodimer and suggestive of interaction between the two proteins in vivo. To further support such an interaction, coimmunoprecipitation experiments using antibody to Plk3 for immunoprecipitation detected P53 by Western blot following subsequent electrophoretic separation. Coimmunoprecipitation was observed in whole cell lysates and in Superdex 200 fractions that contained both Plk3 and P53 (Figure 6c ).
Discussion
The murine Plk3, formerly designated Fnk, was originally cloned as a gene responsive to FGF and other mitogens (Donohue et al., 1995) . Subsequently, a cDNA encoding the human homolog was isolated and designated Prk for proliferation related kinase (Ouyang et al., 1997) . Like murine Plk3, its mRNA is rapidly induced by exposure to serum or cytokines in human cells that had been serum-deprived (Li et al., 1996) , implicating Plk3 in regulation of cell proliferation. Plk3 is a serine/threonine kinase which itself is a target for phosphorylation (Chase et al., 1998) . Phosphorylation of Plk3 had previously been described as a cell cycle specific event, occurring at the time of entry into mitosis (Chase et al., 1998) . However, using a different Western blot (WB) and kinase assays (KA) were performed using P53 as a substrate and using Plk3 or kinase dead Plk3 as the kinase. (c) Antibody to Plk3 was used to immunoprecipitate Plk3 from fraction 13 and whole cell lysate (two middle lanes). The whole cell lysate was used as a control for the presence of P53 and IgG was used as a non-relevant antibody. The immunoprecipitates were subjected to gel electrophoresis and probed with antibody to P53. The immunoprecipitate from fraction 13 showed both phosphorylated and unphosphorylated forms of P53 (second lane) and coimmunoprecipitation was also evident from whole cell lysate (third lane). Direct probing for P53 without coimmunoprecipitation is shown in the fourth lane synchronization protocol, we were unable to confirm this observation. When cells were synchronized by a double thymidine block and followed by Western blot every 2 h after release, there was no evidence of a more slowly migrating Plk3 band that is indicative of phosphorylation, at any time during the cell cycle. The kinetics of cyclin B accumulation and its catastrophic disappearance indicate that synchrony remained tight as cells entered mitosis. Thus, either phosphorylation was transient and sufficiently shortlived to evade detection or phosphorylation was a response to the synchronization procedures previously used.
Since exposure of cells to Nocodazole activates the spindle assembly checkpoint, lysates from cells treated with Nocodazole were fractionated in a sizing column and proteins in each fraction subjected to Western blotting. Untreated cells showed no evidence of Plk3 phosphorylation, and Plk3 eluted principally at a molecular weight of about 150 kDa. In contrast, following Nocodazole treatment, a retarded phosporylated band became evident in fractions containing complexes of about 150 kDa and also in fractions 4600 kDa. The unphosphorylated form eluted in fractions containing complexes between 400 and 500 kDa. Thus, in response to Nocodazole administration, Plk3 becomes phosphorylated and appears to become associated and form complexes with other cellular components. A similar fractionation profile was observed after exposure to ionizing radiation. The responses to these very different cellular insults suggests that Plk3 might serve as a stress response gene and participate in G2 and G2/M checkpoints.
Phosphorylation of Plk3 after DNA damage by ionizing radiation or treatment with MMS is rapid and dependent upon ATM. This phosphorylation is inhibited by treatment with caffeine, consistent with ATM dependence. Similarly, ATM deficient cells are unable to phosphorylate Plk3 following exposure to DNA damaging agents. In wild type cells a phosphorylated form of Plk3 is detectable within 2 min (5 Gy) exposure suggesting that Plk3 is upstream in the ATM-initiated cascade but is not directly phosphorylated by ATM. In Xenopous oocytes, a Plx1 activating kinase has been identified (Kim et al., 1999) and evidence suggests that a mammalian homolog of a yeast sterile kinase, SLK1, may serve to phosphorylate Plk1 in mammalian cells (Qian et al., 1998) . While phosphorylation of Plk3 in mammalian cells requires ATM activity following DNA damage, it is worth noting that Plk3 phosphorylation following spindle disruption by exposure to Nocodazole persists in the absence of ATM. This observation indicates that Plk3 can be phosphorylated in an ATM independent manner when cells are stressed by insults other than those that damage DNA.
Phosphorylation of Plk3 following exposure of cells to ionizing radiation and its dependence upon ATM suggest that Plk3 may participate in the ATMmediated checkpoint. This checkpoint pathway operates, in part, by direct ATM phosphorylation and activation of Chk1 and Chk2, which in turn phosphorylate the dual specificity phosphatase Cdc25c, on Ser216. Phosphorylation of Cdc25c on Ser216 enhances its capacity to bind 14-3-3 proteins, which can affect subcellular localization (Ellinger-Ziegelbauer et al., 2000; Graves et al., 2001) . The role of this phosphorylation event and association with 14-3-3 proteins in the G2 checkpoint, however, remains unclear (Peng et al., 1997) . Activated Chk2 by ATM was mainly shown to regulate G1/S and S phase checkpoint through degradation of Cdc25A (Falck et al., 2001 ) and phosphorylation and activation of P53 (Hirao et al., 2000) respectively. Since Plk3 activity appears to be regulated, in part, by ATM, we asked whether Chk2 might serve as a substrate for Plk3. ATM directly phosphorylates Chk2, preferentially on Thr68 (Melchionna et al., 2000; Matsuoka et al., 1998) . Consistent with a role in this ATM-dependent pathway, we have shown that Plk3 phosphorylates recombinant Chk2 in vitro, preferentially on an amino terminal fragment containing Threonine 68. However, a mutant fragment in which Thr 68 is replaced with an alanine was also actively phosphorylated by recombinant Plk3 suggesting that in vitro, the Chk2 target phosphorylation sites are different for ATM and Plk3, and rendering Plk3 as a candidate upstream kinase for Chk2. That Plk3 and Chk2 physically interact in cells further suggests a possible role for Plk3 in regulating Chk2 activity in vivo. Such a role is further supported by the observation that immunoprecipitated Chk2 from irradiated cells that express Plk3 was more active in phosphorylating Cdc25c peptide compared with Chk2 immunoprecipitated from cells deficient for Plk3.
Since we had previously noted that Plk3 would phosphorylate P53 in vitro (Conn et al., 2000) , we asked whether these proteins might interact within the cell. Size fractionation of MCF10 cell lysates, which express functional P53, showed that in exponentially growing cells, P53 is present in most fractions, but predominantly in fractions containing complexes between about 150 and 500 kDa. After ionizing radiation, the phosphorylated form of P53 co-elutes with a phosphorylated form of Plk3 at molecular weights of about 150 kDa. Association in vivo is supported by co-immunoprecipitation of Plk3 and P53 from these fractions as well as from whole cell lysate; consistent with data from another recent report (Xie et al., 2001b) .
Our results suggest that Plk3 participates in pathways that respond to genotoxic and non-genotoxic stress. The former is ATM dependent whereas the latter is not. Phosphorylation and activation of Plk3 occurs very rapidly following ionizing radiation, suggesting that it is upstream in this pathway. Biochemical data suggest Chk2 is a candidate target for Plk3 and that Chk2 activation may contribute to checkpoint arrest. A potential parallel pathway entails interaction with P53, which also can contribute to checkpoint control. A model that incorporates our biochemical findings is presented in Figure 7 and illustrates the various interactions in which Plk3 can participate.
Materials and methods
Cell culture and synchronization ATM deficient lymphoblastoid cell line, GM 3189C, and its heterozygous counterpart, 3323C were grown at 378C in the presence of 5% CO 2 in RPMI 1640 medium supplemented with 5% fetal bovine serum (FBS) (Gibco-BRL), 2 mM Lglutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. MO59J and MO59K cells were grown in DMEM/F12 supplemented with 10% FBS and antibiotics at 378C and 5% CO 2 . Hela, T47D and MCF10 cells were cultured in DMEM supplemented with 10% FBS and penicillin/ streptomycin (Life Technologies, Inc., Gaithersburg, MD, USA). Daudi cells were grown in DMEM supplemented with 8% FBS and 2% human serum. Exponentially growing cells were arrested in prometaphase by addition of Nocodazole (Sigma) to a final concentration of 100 ng/ml for 8 h. For double thymidine block, cells were placed in 2 mM thymidine for 18 h, at which time the thymidine was removed for 10 h to allow cells arrested at the G1/S boundary and in the S phase to reenter the cell cycle. After 10 h, before cells reentered the next S phase, thymidine was again added to culture dishes to 2 mM for an additional 18 h to collect the majority of cells at the G1/S boundary. Cell cycle progression was monitored by flow cytometry.
Preparation of protein extracts and gel filtration
Protein extracts were prepared using 1% NP-40 lysis buffer (1% NP-40 in 50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EGTA, 30 mg/ml each of DNase and RNase, 25 mM NaF, 25 mM b-glycerol phosphate, and protease inhibitors (10 mg/ ml pepstatin, 10 mg/ml leupeptin, aprotinin (1 : 100), 1 mM PMSF; all from Sigma). Analytical gel filtration was performed using a Superdex-200 FPLC column (Amersham Pharmacia Biotech.) in a buffer containing 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl at a flow rate of 0.5 ml/ min. Molecular weight markers used to calibrate the column were: Thyroglobulin (670 000), ferritin (440 000), g-globulin (158 000), bovine serum albumin (67 000) and ovalbumin (43 000). 1 ml fractions were collected; about 20 mg protein from each fraction was resolved on a 10% polyacrylamide gel and immunoblotted.
Immunoprepicitation, kinase assays and immunoblotting
For immunoprecipitation, lysate (250 mg) was pre-cleared with 30 ml of protein A/G-Plus agarose (Santa Cruz Biotechnology) for 1 h followed by incubation with 2 mg of Plk3 antibody (Transduction Labs, Lexington, KY, USA), 2 mg of GFP monoclonal antibody (Boehringer Mannheim), 2 mg of P53 antibody (a gift from Dr K Fukuzawa, University of Cincinnati) or 2 mg of Chk2 rabbit polyclonal antibody (Blasina et al., 1999a,b) and protein A/G-agarose beads (30 ml) for 3 h. Immunocomplexes were then washed at least three times in ice-cold lysis buffer (50 mM Tris-HCl pH 7.4, 0.2% Triton X-100, 0.3% NP-40, 150 mM NaCl, 1 mM PMSF, pepstatin (1 mg/ml), Leupeptin (2 mg/ml), aprotinin (2 mg/ml), 25 mM NaF, 1 mM EDTA and 1 mM Na 3 VO 4 ), followed by one wash in kinase buffer (30 mM HEPES pH 7.4, 10 mM MgCl 2 and 1 mM DTT. Immunocomplexes were resuspended in 20 ml of kinase buffer with 1 mg of protein to be tested, 1 mg of substrate, 10 mM ATP, and 10 mCi of [g 32 P]ATP. Reactions were then allowed proceeding for 30 min at 308C, at which time they were extinguished by the addition of 66SDS loading buffer. Kinase reactions were then boiled for 10 min and fractionated by SDS -PAGE on 10% acrylamide gels. The biochemically purified ATM protein used in the kinase reactions was a gift from K Dixon and G Oakley (University of Cincinnati).
For Western blot analysis, cells were lysed in ice-cold lysis buffer, precleared by centrifugation at 14 000 g for 15 min at 48C. 20 mg of lysate were fractionated on 10% acrylamide gels. Proteins were transferred from the gel to an immobilon-P polyvinylidene difluoride (Millipore, Bedford, MA, USA) membrane, followed by blotting with monoclonal antibodies. Western blots were visualized by enhanced chemiluminescence (Amersham).
Abbreviations ATM, ataxia telangiectasia mutated; CIP, calf intestinal phosphatase; FPLC, fast protein liquid chromatography; Plk, polo-like kinase. 
